Royal Bank of Canada Trims Stake in ZIOPHARM Oncology Inc (ZIOP)

Royal Bank of Canada reduced its position in ZIOPHARM Oncology Inc (NASDAQ:ZIOP) by 12.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,537 shares of the biotechnology company’s stock after selling 3,219 shares during the quarter. Royal Bank of Canada’s holdings in ZIOPHARM Oncology were worth $147,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. Tudor Investment Corp ET AL lifted its position in ZIOPHARM Oncology by 390.4% in the second quarter. Tudor Investment Corp ET AL now owns 63,304 shares of the biotechnology company’s stock worth $394,000 after purchasing an additional 50,395 shares during the period. Voya Investment Management LLC lifted its position in ZIOPHARM Oncology by 21.9% in the second quarter. Voya Investment Management LLC now owns 60,782 shares of the biotechnology company’s stock worth $378,000 after purchasing an additional 10,913 shares during the period. Parametric Portfolio Associates LLC lifted its position in ZIOPHARM Oncology by 6.0% in the second quarter. Parametric Portfolio Associates LLC now owns 85,837 shares of the biotechnology company’s stock worth $534,000 after purchasing an additional 4,826 shares during the period. Vanguard Group Inc. lifted its position in ZIOPHARM Oncology by 7.6% in the second quarter. Vanguard Group Inc. now owns 7,864,470 shares of the biotechnology company’s stock worth $48,917,000 after purchasing an additional 553,933 shares during the period. Finally, Northern Trust Corp lifted its position in ZIOPHARM Oncology by 10.1% in the second quarter. Northern Trust Corp now owns 1,630,858 shares of the biotechnology company’s stock worth $10,144,000 after purchasing an additional 149,067 shares during the period. 41.90% of the stock is owned by hedge funds and other institutional investors.

Shares of ZIOPHARM Oncology Inc (NASDAQ ZIOP) opened at $4.43 on Monday. ZIOPHARM Oncology Inc has a 12 month low of $4.03 and a 12 month high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.13). The business had revenue of $1.60 million during the quarter, compared to analyst estimates of $1.66 million. During the same quarter last year, the business posted ($0.11) earnings per share. The business’s quarterly revenue was up .0% compared to the same quarter last year. analysts forecast that ZIOPHARM Oncology Inc will post -0.54 EPS for the current fiscal year.

Several research analysts have issued reports on ZIOP shares. Zacks Investment Research upgraded ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research note on Friday, November 10th. HC Wainwright reiterated a “buy” rating and set a $9.50 price objective on shares of ZIOPHARM Oncology in a research note on Tuesday, November 7th. BidaskClub upgraded ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Finally, ValuEngine upgraded ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Monday, August 28th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $12.58.

In other news, CEO Laurence James Neil Cooper acquired 6,440 shares of the stock in a transaction that occurred on Wednesday, November 8th. The stock was purchased at an average cost of $4.68 per share, for a total transaction of $30,139.20. Following the completion of the transaction, the chief executive officer now directly owns 1,083,731 shares in the company, valued at $5,071,861.08. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 10.40% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Royal Bank of Canada Trims Stake in ZIOPHARM Oncology Inc (ZIOP)” was first posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://transcriptdaily.com/2017/11/27/royal-bank-of-canada-trims-stake-in-ziopharm-oncology-inc-ziop.html.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Want to see what other hedge funds are holding ZIOP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZIOPHARM Oncology Inc (NASDAQ:ZIOP).

Institutional Ownership by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply